Answers are grounded in this paper and cite their sources.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease whose pathogenesis is associated with neuroinflammation and dysregulation of innate immunity. Animal models and cell culture studies suggest a possible involvement of inflammasome-mediated inflammatory pathways and pyroptosis in the pathogenesis of ALS, but clinical data from patients with ALS are currently limited. The results of a comparative study of the levels of soluble markers potentially associated with inflammasome-associated inflammation and pyroptosis in the blood serum and cerebrospinal fluid (CSF) of patients with ALS are presented, and their relationship with clinical and some genetic characteristics of patients is analyzed. We compared the concentrations of interleukin-1β (IL-1β), interleukin-18 (IL-18), and gasdermin D, determined by ELISA in the blood serum and CSF of patients with ALS and in the control group, and analyzed their dependence on the clinical phenotype of the disease and the presence of mutations in genes SOD1 and c9orf72. An increase in the concentration of gasdermin D in the blood serum and IL-1β in the CSF of patients with ALS was revealed. Increased IL-1β level in CSF was associated with the presence of the (GGGGCC)n repeat expansion in the c9orf72 gene, and the serum gasdermin D level was associated with the clinical phenotype of the disease. The obtained data indicate the possible involvement of inflammatory processes potentially associated with inflammasome-associated inflammation in the pathogenesis of ALS and emphasize the advisability of their further study.
No takes yet. Share an insight, caveat, or question.
Shevchuk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: